{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:29:08Z","timestamp":1773800948956,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.clinthera.2015.12.015","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T18:01:05Z","timestamp":1453399265000},"page":"348-357","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending\u2013dose and Multiple-dose, Parallel-group Study"],"prefix":"10.1016","volume":"38","author":[{"given":"Hongzhong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.12.015_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","article-title":"Hyperparathyroidism","volume":"374","author":"Fraser","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.12.015_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.ki.5002287","article-title":"Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics","volume":"74","author":"Goodman","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.12.015_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/MED.0b013e3283400945","article-title":"Renal bone disease","volume":"17","author":"Sprague","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.clinthera.2015.12.015_bib4","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.12.015_bib5","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.12.015_bib6","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.12.015_bib7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.ki.5002028","article-title":"Uremia-related vascular calcification: more than apatite deposition","volume":"71","author":"Verberckmoes","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.12.015_bib8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.12.015_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/ndt\/17.5.723","article-title":"Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphatemia","volume":"17","author":"Locatelli","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2015.12.015_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride","volume":"48","author":"Padhi","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.12.015_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5414\/CN107285","article-title":"Cinacalcet for hemodialyzed patients with or without a high PTH level to control serum calcium and phosphorus: ECO (evaluation of cinacalcet HCl outcome) study","volume":"78","author":"Yokoyama","year":"2012","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.clinthera.2015.12.015_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.12.015_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-200746060-00003","article-title":"Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole","volume":"46","author":"Harris","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.12.015_bib14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":"Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily","volume":"44","author":"Harris","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2015.12.015_bib15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1600-6143.2007.02136.x","article-title":"Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation","volume":"8","author":"Serra","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clinthera.2015.12.015_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/00044011-200828100-00004","article-title":"Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment: phase I, open-label, parallel-group, single-dose, single-centre study","volume":"28","author":"Padhi","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2015.12.015_bib17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/17425255.2011.585969","article-title":"Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs","volume":"7","author":"Sai","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2015.12.015_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2710.2011.01298.x","article-title":"Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations","volume":"37","author":"Yin","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2015.12.015_bib19","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1124\/dmd.104.000604","article-title":"Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models","volume":"32","author":"Kumar","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2015.12.015_bib20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.clinthera.2012.03.058","article-title":"Pharmacokinetic and pharmacodynamic properties of the calcimimetic agent cinacalcet (KRN1493) in healthy male Korean subjects: a randomized, open-label, single ascending-dose, parallel-group study","volume":"34","author":"Lee","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2015.12.015_bib21","first-page":"941","article-title":"Phase I study of KRN1493 (cinacalcet hydrochloride) in healthy male volunteers: pharmacokinetics, pharmacodynamics and safety after single oral dosing","volume":"35","author":"Junichi","year":"2007","journal-title":"Jpn Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.12.015_bib22","unstructured":"World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html. 2008. Accessed January 7, 2011."},{"key":"10.1016\/j.clinthera.2015.12.015_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jpba.2011.10.022","article-title":"Determination of cinacalcet hydrochloride in human plasma by liquid chromatography\u2013tandem mass spectrometry","volume":"61","author":"Yang","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.clinthera.2015.12.015_bib24","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1023\/A:1026451721686","article-title":"Confidence interval criteria for assessment of dose proportionality","volume":"17","author":"Smith","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2015.12.015_bib25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/clinchem\/38.3.400","article-title":"Circadian changes in plasma phosphate concentration, urinary phosphate excretion, and cellular phosphate shifts","volume":"38","author":"Kemp","year":"1992","journal-title":"Clin Chem"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815013752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815013752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T06:54:53Z","timestamp":1600066493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815013752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0149291815013752"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.12.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}